JP2021506786A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021506786A5 JP2021506786A5 JP2020532551A JP2020532551A JP2021506786A5 JP 2021506786 A5 JP2021506786 A5 JP 2021506786A5 JP 2020532551 A JP2020532551 A JP 2020532551A JP 2020532551 A JP2020532551 A JP 2020532551A JP 2021506786 A5 JP2021506786 A5 JP 2021506786A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- cdr
- antibody
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 197
- 230000001605 fetal effect Effects 0.000 claims description 62
- 230000000735 allogeneic effect Effects 0.000 claims description 44
- 208000023275 Autoimmune disease Diseases 0.000 claims description 43
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 23
- 230000035935 pregnancy Effects 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 15
- 230000037396 body weight Effects 0.000 claims description 8
- 230000004584 weight gain Effects 0.000 claims description 6
- 235000019786 weight gain Nutrition 0.000 claims description 6
- 230000003442 weekly effect Effects 0.000 claims description 5
- 230000036266 weeks of gestation Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
- 201000010099 disease Diseases 0.000 description 27
- 230000009385 viral infection Effects 0.000 description 19
- 230000028993 immune response Effects 0.000 description 15
- 238000006467 substitution reaction Methods 0.000 description 15
- 206010039710 Scleroderma Diseases 0.000 description 14
- 230000001363 autoimmune Effects 0.000 description 14
- 208000007502 anemia Diseases 0.000 description 13
- 206010025135 lupus erythematosus Diseases 0.000 description 13
- 201000001981 dermatomyositis Diseases 0.000 description 11
- 208000005987 polymyositis Diseases 0.000 description 11
- 208000011580 syndromic disease Diseases 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 8
- 208000001640 Fibromyalgia Diseases 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 8
- 230000002949 hemolytic effect Effects 0.000 description 8
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 7
- 208000023328 Basedow disease Diseases 0.000 description 7
- 208000015023 Graves' disease Diseases 0.000 description 7
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 7
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 201000004384 Alopecia Diseases 0.000 description 5
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 5
- 206010009900 Colitis ulcerative Diseases 0.000 description 5
- 201000004681 Psoriasis Diseases 0.000 description 5
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 description 5
- 231100000360 alopecia Toxicity 0.000 description 5
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 201000003068 rheumatic fever Diseases 0.000 description 5
- 206010000234 Abortion spontaneous Diseases 0.000 description 4
- 208000026872 Addison Disease Diseases 0.000 description 4
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 4
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 description 4
- 201000002829 CREST Syndrome Diseases 0.000 description 4
- 208000031229 Cardiomyopathies Diseases 0.000 description 4
- 208000015943 Coeliac disease Diseases 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 4
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 4
- 208000007465 Giant cell arteritis Diseases 0.000 description 4
- 208000001204 Hashimoto Disease Diseases 0.000 description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 4
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 4
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 4
- 206010021263 IgA nephropathy Diseases 0.000 description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- 208000003456 Juvenile Arthritis Diseases 0.000 description 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 4
- 208000027530 Meniere disease Diseases 0.000 description 4
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 4
- 206010028372 Muscular weakness Diseases 0.000 description 4
- 208000033464 Reiter syndrome Diseases 0.000 description 4
- 208000025747 Rheumatic disease Diseases 0.000 description 4
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 4
- 201000009594 Systemic Scleroderma Diseases 0.000 description 4
- 206010042953 Systemic sclerosis Diseases 0.000 description 4
- 206010003230 arteritis Diseases 0.000 description 4
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 4
- 201000003278 cryoglobulinemia Diseases 0.000 description 4
- CKSJXOVLXUMMFF-UHFFFAOYSA-N exalamide Chemical compound CCCCCCOC1=CC=CC=C1C(N)=O CKSJXOVLXUMMFF-UHFFFAOYSA-N 0.000 description 4
- 229950010333 exalamide Drugs 0.000 description 4
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 4
- 208000007475 hemolytic anemia Diseases 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 208000003532 hypothyroidism Diseases 0.000 description 4
- 230000002989 hypothyroidism Effects 0.000 description 4
- 208000026278 immune system disease Diseases 0.000 description 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 208000015994 miscarriage Diseases 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 4
- 230000036473 myasthenia Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 208000002574 reactive arthritis Diseases 0.000 description 4
- 230000000552 rheumatic effect Effects 0.000 description 4
- 201000000306 sarcoidosis Diseases 0.000 description 4
- 230000037390 scarring Effects 0.000 description 4
- 208000000995 spontaneous abortion Diseases 0.000 description 4
- 206010043207 temporal arteritis Diseases 0.000 description 4
- 230000001256 tonic effect Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 208000008190 Agammaglobulinemia Diseases 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 3
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 3
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 3
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 3
- 208000011200 Kawasaki disease Diseases 0.000 description 3
- 201000002661 Spondylitis Diseases 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 208000010928 autoimmune thyroid disease Diseases 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 208000002741 leukoplakia Diseases 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 3
- 206010028417 myasthenia gravis Diseases 0.000 description 3
- 208000021356 neonatal antiphospholipid syndrome Diseases 0.000 description 3
- 208000021287 neonatal autoimmune hemolytic anemia Diseases 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 206010043554 thrombocytopenia Diseases 0.000 description 3
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 2
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
- 206010019263 Heart block congenital Diseases 0.000 description 2
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 2
- 208000028622 Immune thrombocytopenia Diseases 0.000 description 2
- 208000005777 Lupus Nephritis Diseases 0.000 description 2
- 201000002481 Myositis Diseases 0.000 description 2
- 206010029379 Neutrophilia Diseases 0.000 description 2
- 206010065159 Polychondritis Diseases 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 201000004395 congenital heart block Diseases 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 231100000562 fetal loss Toxicity 0.000 description 2
- 230000010370 hearing loss Effects 0.000 description 2
- 231100000888 hearing loss Toxicity 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 208000015557 immune complex mediated vasculitis Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 108010068617 neonatal Fc receptor Proteins 0.000 description 2
- 206010040400 serum sickness Diseases 0.000 description 2
- 208000002254 stillbirth Diseases 0.000 description 2
- 231100000537 stillbirth Toxicity 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 description 2
- 208000007887 Alphavirus Infections Diseases 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000004293 Chikungunya Fever Diseases 0.000 description 1
- 206010067256 Chikungunya virus infection Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 208000010772 Dog disease Diseases 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 206010014909 Enterovirus infection Diseases 0.000 description 1
- 206010054261 Flavivirus infection Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000019758 Hypergammaglobulinemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 241000710908 Murray Valley encephalitis virus Species 0.000 description 1
- 208000021908 Myocardial disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 208000004692 Pneumovirus Infections Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010057293 West Nile viral infection Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 102220351004 c.68C>T Human genes 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000021601 lentivirus infection Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000008795 neuromyelitis optica Diseases 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 102220214529 rs1060504748 Human genes 0.000 description 1
- 102200056122 rs11570605 Human genes 0.000 description 1
- 102220141469 rs543096490 Human genes 0.000 description 1
- 102220124960 rs754095587 Human genes 0.000 description 1
- 102220323800 rs774193307 Human genes 0.000 description 1
- 102220124425 rs868228427 Human genes 0.000 description 1
- 102220098934 rs878854576 Human genes 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023177190A JP7690538B2 (ja) | 2017-12-13 | 2023-10-13 | ＦｃＲｎ抗体およびその使用方法 |
| JP2025089576A JP2025143252A (ja) | 2017-12-13 | 2025-05-29 | ＦｃＲｎ抗体およびその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762598402P | 2017-12-13 | 2017-12-13 | |
| US62/598,402 | 2017-12-13 | ||
| US201862701354P | 2018-07-20 | 2018-07-20 | |
| US62/701,354 | 2018-07-20 | ||
| PCT/US2018/065568 WO2019118791A1 (en) | 2017-12-13 | 2018-12-13 | Fcrn antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023177190A Division JP7690538B2 (ja) | 2017-12-13 | 2023-10-13 | ＦｃＲｎ抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021506786A JP2021506786A (ja) | 2021-02-22 |
| JP2021506786A5 true JP2021506786A5 (enExample) | 2021-05-13 |
| JP7420720B2 JP7420720B2 (ja) | 2024-01-23 |
Family
ID=65041911
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020532551A Active JP7420720B2 (ja) | 2017-12-13 | 2018-12-13 | ＦｃＲｎ抗体およびその使用方法 |
| JP2023177190A Active JP7690538B2 (ja) | 2017-12-13 | 2023-10-13 | ＦｃＲｎ抗体およびその使用方法 |
| JP2025089576A Pending JP2025143252A (ja) | 2017-12-13 | 2025-05-29 | ＦｃＲｎ抗体およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023177190A Active JP7690538B2 (ja) | 2017-12-13 | 2023-10-13 | ＦｃＲｎ抗体およびその使用方法 |
| JP2025089576A Pending JP2025143252A (ja) | 2017-12-13 | 2025-05-29 | ＦｃＲｎ抗体およびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11773168B2 (enExample) |
| EP (1) | EP3723802A1 (enExample) |
| JP (3) | JP7420720B2 (enExample) |
| KR (1) | KR20200098604A (enExample) |
| CN (1) | CN111712259A (enExample) |
| AU (1) | AU2018386193B2 (enExample) |
| BR (1) | BR112020011310A2 (enExample) |
| CA (1) | CA3085751A1 (enExample) |
| IL (1) | IL275070A (enExample) |
| SG (1) | SG11202005021PA (enExample) |
| WO (1) | WO2019118791A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202007232WA (en) | 2015-01-30 | 2020-09-29 | Momenta Pharmaceuticals Inc | Fcrn antibodies and methods of use thereof |
| KR20200096786A (ko) | 2017-12-08 | 2020-08-13 | 아르제넥스 비브이비에이 | 전신 중증 근무력증의 치료를 위한 FcRn 길항제의 용도 |
| AU2018386193B2 (en) * | 2017-12-13 | 2025-04-24 | Momenta Pharmaceuticals, Inc. | FcRn antibodies and methods of use thereof |
| US12202900B2 (en) | 2018-06-08 | 2025-01-21 | argenx BV | Compositions and methods for treating immune thrombocytopenia |
| JP2022542430A (ja) * | 2019-08-01 | 2022-10-03 | ヤンセン バイオテツク，インコーポレーテツド | Ｆｃｒｎ抗体およびその使用の方法 |
| CA3163172A1 (en) | 2020-01-08 | 2021-07-15 | Peter Verheesen | Methods for treating pemphigus disorders |
| CA3183153A1 (en) * | 2020-06-17 | 2021-12-23 | Christian HINDERER | Compositions and methods for treatment of gene therapy patients |
| TW202233236A (zh) * | 2020-11-06 | 2022-09-01 | 美商健生生物科技公司 | Fcrn抗體及其使用方法 |
| CN116234827A (zh) * | 2021-09-03 | 2023-06-06 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别FcRn的抗体及其应用 |
| CN114129730A (zh) * | 2021-09-16 | 2022-03-04 | 宁夏大学 | FcRn抑制剂在制备降低炎症反应和/或防治结核病的试剂或药物中的应用 |
| AR128284A1 (es) * | 2022-01-17 | 2024-04-10 | argenx BV | Métodos para tratar a pacientes con una enfermedad mediada por autoanticuerpos |
| CN119630697A (zh) | 2022-06-15 | 2025-03-14 | 阿根思有限公司 | Ph依赖性hsa结合分子及使用方法 |
| AR133188A1 (es) | 2023-07-05 | 2025-09-03 | Ablynx Nv | ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG |
| TW202527982A (zh) | 2023-09-11 | 2025-07-16 | 美商默門塔醫藥公司 | Fcrn抗體之醫藥組成物 |
| WO2025186787A1 (en) * | 2024-03-08 | 2025-09-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003068259A1 (fr) | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| US7662928B2 (en) | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| JP2007501847A (ja) | 2003-08-08 | 2007-02-01 | ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク | 自己／同種免疫状態の治療用抗ＦｃＲｎ抗体 |
| CN101124245A (zh) | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| DK1865986T3 (en) | 2005-03-08 | 2016-04-11 | Pfizer Prod Inc | The anti-CTLA-4 antibody compositions |
| CA2637929A1 (en) | 2006-01-25 | 2007-08-02 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatement of auto/allo immune conditions |
| WO2007104529A2 (en) | 2006-03-13 | 2007-09-20 | Ablynx N.V. | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| CA3131470A1 (en) | 2008-04-25 | 2009-10-29 | Takeda Pharmaceutical Company Limited | Fc receptor binding proteins |
| JP5683581B2 (ja) | 2009-06-30 | 2015-03-11 | リサーチ ディベロップメント ファウンデーション | 免疫グロブリンＦｃポリペプチド |
| US9067997B2 (en) * | 2011-05-25 | 2015-06-30 | Innate Pharma Sa | Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders |
| CN103619353B (zh) | 2011-06-02 | 2016-01-06 | 戴埃克斯有限公司 | Fc受体结合蛋白 |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| US20130323242A1 (en) | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| US9844594B2 (en) | 2012-12-18 | 2017-12-19 | Merck Sharp & Dohme Corp. | Liquid formulations for an anti-TNF α antibody |
| ES2802274T3 (es) | 2013-05-02 | 2021-01-18 | Momenta Pharmaceuticals Inc | Glicoproteínas sialiladas |
| KR101815265B1 (ko) | 2013-06-20 | 2018-01-04 | 한올바이오파마주식회사 | FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
| NZ737666A (en) | 2014-04-30 | 2018-10-26 | Hanall Biopharma Co Ltd | Antibody binding to fcrn for treating autoimmune diseases |
| SG10202007232WA (en) | 2015-01-30 | 2020-09-29 | Momenta Pharmaceuticals Inc | Fcrn antibodies and methods of use thereof |
| CA3022547A1 (en) * | 2015-05-12 | 2016-11-17 | Syntimmune, Inc. | Humanized affinity matured anti-fcrn antibodies |
| CA3032415A1 (en) | 2016-07-29 | 2018-02-01 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
| JP6913527B2 (ja) | 2017-06-22 | 2021-08-04 | 株式会社小松製作所 | 油圧ポンプおよびモータ |
| KR20200096786A (ko) | 2017-12-08 | 2020-08-13 | 아르제넥스 비브이비에이 | 전신 중증 근무력증의 치료를 위한 FcRn 길항제의 용도 |
| AU2018386193B2 (en) | 2017-12-13 | 2025-04-24 | Momenta Pharmaceuticals, Inc. | FcRn antibodies and methods of use thereof |
| EP3762027A4 (en) | 2018-02-13 | 2022-06-15 | The Brigham & Women's Hospital, Inc. | THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES |
| CA3106669A1 (en) | 2018-07-20 | 2020-01-30 | Momenta Pharmaceuticals, Inc. | Compositions of fcrn antibodies and methods of use thereof |
| EP3823978A4 (en) | 2018-07-20 | 2022-12-14 | Momenta Pharmaceuticals, Inc. | Fcrn antibody compositions |
| MX2021004351A (es) | 2018-10-16 | 2021-05-31 | UCB Biopharma SRL | Metodo para el tratamiento de miastenia grave. |
| JP2022542430A (ja) | 2019-08-01 | 2022-10-03 | ヤンセン バイオテツク，インコーポレーテツド | Ｆｃｒｎ抗体およびその使用の方法 |
| TW202233236A (zh) | 2020-11-06 | 2022-09-01 | 美商健生生物科技公司 | Fcrn抗體及其使用方法 |
-
2018
- 2018-12-13 AU AU2018386193A patent/AU2018386193B2/en active Active
- 2018-12-13 JP JP2020532551A patent/JP7420720B2/ja active Active
- 2018-12-13 WO PCT/US2018/065568 patent/WO2019118791A1/en not_active Ceased
- 2018-12-13 CA CA3085751A patent/CA3085751A1/en active Pending
- 2018-12-13 US US16/771,147 patent/US11773168B2/en active Active
- 2018-12-13 KR KR1020207019955A patent/KR20200098604A/ko active Pending
- 2018-12-13 BR BR112020011310-7A patent/BR112020011310A2/pt unknown
- 2018-12-13 SG SG11202005021PA patent/SG11202005021PA/en unknown
- 2018-12-13 EP EP18836751.0A patent/EP3723802A1/en active Pending
- 2018-12-13 CN CN201880089334.7A patent/CN111712259A/zh active Pending
-
2020
- 2020-06-02 IL IL275070A patent/IL275070A/en unknown
-
2023
- 2023-08-18 US US18/452,346 patent/US20240158509A1/en active Pending
- 2023-10-13 JP JP2023177190A patent/JP7690538B2/ja active Active
-
2025
- 2025-05-29 JP JP2025089576A patent/JP2025143252A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021506786A5 (enExample) | ||
| JP2024016042A5 (enExample) | ||
| JP2019526540A5 (enExample) | ||
| JP7442575B2 (ja) | Ｆｃｒｎ抗体及びその使用方法 | |
| US20240132603A1 (en) | Ccr8 antibody and application thereof | |
| KR100255717B1 (ko) | 항체의 생산방법 | |
| JP7420720B2 (ja) | ＦｃＲｎ抗体およびその使用方法 | |
| WO2020060924A1 (en) | Use of a cd4/cd8 bispecific antibody for the treatment of autoimmune/inflammatory disorders | |
| ES2389781T3 (es) | Tratamiento de la inflamación articular crónica mediante un anticuerpo aglicosilado anti-CD3 | |
| US20140199299A1 (en) | Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists | |
| BR112020012011A2 (pt) | moléculas de ligação a antígeno biespecífica isolada e de ligação a antígeno biespecífica ou cadeia de imunoglobulina, composição farmacêutica, recipiente ou dispositivo de injeção, ácido nucleico isolado, vetor isolado, célula hospedeira isolada, métodos para tratar uma doença ou condição, para tratar uma condição de lipodistrofia em um sujeito, para produzir uma molécula de ligação a antígeno biespecífica, e, para administrar uma molécula de ligação a antígeno biespecífica isolada ou composição farmacêutica. | |
| JP2025138661A (ja) | Ｆｃｒｎ抗体およびその使用の方法 | |
| EA028678B1 (ru) | Нейтрализующие пролактиновый рецептор антитела и их терапевтическое применение | |
| KR20230117575A (ko) | Fcrn 항체 및 이의 사용 방법 | |
| US8367061B2 (en) | Anti-idiotype monoclonal antibodies mimicking the HIV gp120 CD4-binding (CD4bs) | |
| ES2274542T3 (es) | Anticuerpos frente al receptor del interferon alfa/beta. | |
| CN114751982B (zh) | 抗人ngf抗体及其制备方法和用途 | |
| ES3001197T3 (es) | Agente de unión anti-adrenomedulina (ADM) para su uso en la terapia o prevención de síntomas de enfermedad | |
| WO2015098813A1 (ja) | 新規抗ヒトｂｄｃａ－２抗体 | |
| CN105770889B (zh) | 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用 | |
| JPH11263799A (ja) | 受精能を変化させる方法 | |
| US20210292413A1 (en) | Anti-siglec antibody, pharmaceutical composition comprising the same, and uses thereof | |
| ES2835923T3 (es) | Anticuerpo antiesclerostina, fragmento de unión a antígeno y uso médico del mismo | |
| JP2024073462A (ja) | 抗ｒａｎｋｌ抗体およびその使用 | |
| WO2010132872A1 (en) | Combination therapies and methods using anti-cd3 modulating agents and anti-tnf antagonists |